论文部分内容阅读
由于ＡＲＦ非常高的发病率和死亡率，以及缺乏有效的预防和治疗药物，促使许多研究者开始对多巴胺制剂（ＤＡＡ）研究。但大剂量多巴胺（非选择性ＤＡＡ）副作用和低剂量无效果，使人们考虑用高选择性多巴胺兴奋剂来预防和治疗ＡＲＦ。研究表明ＤＡ－１兴奋剂（如ｆｅｎｏｌｄｏｎｐａｍ）具有良好的肾脏效应，包括降低ＲＶＲ，增加ＲＢＦ、ＧＲＦ、钠分泌和尿量，可以用来预防和治疗ＡＲＦ。即使大剂量应用选择性ＤＡ－１兴奋剂也不刺激ＤＡ－２受体或肾上腺素受体，因此较少发生肾脏外副作用
Due to the very high morbidity and mortality of ARF and the lack of effective prophylactic and therapeutic drugs, many researchers have been urged to start research on dopamine preparations (DAAs). However, high doses of dopamine (non-selective DAA) side effects and low dose no effect, so that people consider the use of highly selective dopamine agonists to prevent and treat ARF. Studies have shown that DA-1 stimulants (such as fenoldonpam) have good renal effects, including reduced RVR, increased RBF, GRF, sodium secretion and urine output, which can be used to prevent and treat ARF. Even though high-dose selective DA-1 agonists do not stimulate the DA-2 receptor or adrenoceptors, fewer adverse renal effects occur